Kazakhstan to produce two million doses of QazVac vaccine by end of 2021

It’s been proved that the Kazakh QazVac vaccine forms a stable immunity to the virus and is among the few to be included in the list of the World Health Organization. Thus, Kazakhstan is among the 10 countries that have developed their own vaccine. Two million doses of the domestic vaccine will be manufactured by the end of the year. A corresponding agreement has already been signed between the SK Pharmacy and the Research Institute for Biological Safety Problems. In the future, it is planned to produce 500,000 to 600,000 doses of the vaccine every month.

“The first vaccine batch in the amount of 50,000 doses were produced at the Research Institute for Biological Safety Problems. Other production sites are also currently being considered at the government level together with other state bodies,” said Marat Shoranov, Kazakh First Vice Minister Of Health.

To date, 6,000 doses of QazVac have been delivered to Nur-Sultan and Almaty. Shymkent city, as well as Karagandy, East Kazakhstan and Almaty regions, will each receive 4,000 doses. One of the advantages of the domestic vaccine is that the process of its delivery does not require complex refrigeration units and it can be transported at a temperature of two to eight degrees Celsius. Jabs are administered twice at 21-day intervals. Vaccine developers say that the QazVac COVID-19 vaccine is resistant to all virus mutations.

According to the latest data from the Kazakh Health Ministry, a total of about 894,000 Kazakh citizens have received the first dose of the coronavirus vaccine by now. Of these, almost 166,000 people have already been vaccinated with the second dose.


Translation by Assem Zhanmukhanova

Editing by Galiya Khassenkhanova